Farnesoid X receptor modulators: a patent review (Q37766898)

22 August 2017

1 reference

title

Farnesoid X receptor modulators: a patent review (English)

1 reference

22 August 2017

Matthew Lantz Crawley

series ordinal

1

1 reference

PubMed ID

20569093

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

1 reference

22 August 2017

20

1 reference

22 August 2017

8

1 reference

22 August 2017

1047-1057

1 reference

Identification of a nuclear receptor that is activated by farnesol metabolites

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Bile acids: natural ligands for an orphan nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Identification of a nuclear receptor for bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Farnesoid X receptor: from structure to potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Targeting farnesoid X receptor for liver and metabolic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Role of bile acids and bile acid receptors in metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

The farnesoid X receptor: a novel drug target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Identification of a chemical tool for the orphan nuclear receptor FXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

FXR agonist activity of conformationally constrained analogs of GW 4064

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.496777

10.1517/13543776.2010.496777

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20569093